Clincosm LogoSign in Get a demo

Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment

Sponsor
Tanta University (Other)
Overall Status
Completed
CT.gov ID
NCT04353336
Collaborator
(none)
194
Enrollment
1
Location
2
Arms
3.3
Actual Duration (Months)
59
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Chloroquine or hydroxychloroquine in COVID-19 treatment

Condition or Disease Intervention/Treatment Phase
  • Drug: Chloroquine or Hydroxychloroquine
 Phase 2/Phase 3

Detailed Description

Clinical Study Evaluating the Efficacy of Chloroquine or hydroxychloroquine in COVID-19 treatment

Study Design

Study Type:
Interventional
Actual Enrollment :
194 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment
Actual Study Start Date :
Mar 23, 2020
Actual Primary Completion Date :
Jun 1, 2020
Actual Study Completion Date :
Jul 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Chloroquine or Hydroxychloroquine

Chloroquine or Hydroxychloroquine with standard of care treatment.

Drug: Chloroquine or Hydroxychloroquine
Chloroquine or Hydroxychloroquine
Other Names:
  • alexoquine, chloroquine, Hydroquine

    		•
    No Intervention: No intervention

    standard of care treatment alone.

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients with cure or death [1 month]

      the number of patients with cure or death

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Covid 19 patients
    Exclusion Criteria:

    • Allergy or contraindication to the drug

    • Pregnant or lactating

    • Patients with cardiac problems

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tanta University, Assiut University Tanta Egypt 35111

    Sponsors and Collaborators

    • Tanta University

    Investigators

    • Principal Investigator: sherief Abd-Elsalam, Ass. Prof., Tanta University - Faculty of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University
    ClinicalTrials.gov Identifier:
    NCT04353336
    Other Study ID Numbers:
    • chloroquine covid
    First Posted:
    Apr 20, 2020
    Last Update Posted:
    Aug 2, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    COVID-19
    Coronavirus Infections
    Hydroxychloroquine
    Chloroquine
    Chloroquine diphosphate

    Study Results

    No Results Posted as of Aug 2, 2021